{"product_id":"9783031903397","title":"Prostate Cancer from a Nuclear Oncology Perspective A Personal Journey","description":"\u003ch1\u003eProstate Cancer from a Nuclear Oncology Perspective\u003c\/h1\u003e\u003ch2\u003eA Personal Journey\u003c\/h2\u003e\u003ch3\u003eKalevi Kairemo\u003c\/h3\u003e\u003cdiv\u003e\u003cb\u003eMedical \/ Radiology, Radiotherapy \u0026amp; Nuclear Medicine\u003c\/b\u003e\u003c\/div\u003e\u003cbr\u003e\u003cdiv\u003e\n\u003cp class=\"MsoNormal\"\u003e\u003cspan style=\"mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US;\"\u003eThis book provides a comprehensive review of innovative diagnostic methods for prostate cancer, with a particular emphasis on the development of PET radiopharmaceuticals. The author has had the privilege to introduce several tracers into clinical routine practice, including Na\u003csup\u003e18\u003c\/sup\u003eF, \u003csup\u003e18\u003c\/sup\u003eF-FCH, \u003csup\u003e18\u003c\/sup\u003eF-FACBC, \u003csup\u003e68\u003c\/sup\u003eGa-PSMA11, \u003csup\u003e18\u003c\/sup\u003eF-PSMA-1007, and \u003csup\u003e18\u003c\/sup\u003eF-DCFPyL. Thus, indications in various prostate cancer subgroups are discussed in detail, weighing the pros and cons in clinical practice. In the authors´ practice radiation therapy has been more important and surgical applications; therefore, PET based dose planning is presented in detail. Furthermore, the author has closely followed the development of radiopharmaceutical treatments, particularly in the context of bone pain palliation using radiopharmaceuticals, such as \u003csup\u003e89\u003c\/sup\u003eSrCl\u003csub\u003e2\u003c\/sub\u003e, \u003csup\u003e186\u003c\/sup\u003eReHEDP, \u003csup\u003e153\u003c\/sup\u003eSmEDTMP, \u003csup\u003e117m\u003c\/sup\u003eSnDTPA, and \u003csup\u003e223\u003c\/sup\u003eRaCl\u003csub\u003e2\u003c\/sub\u003e, and targeted treatments (\u003csup\u003e177\u003c\/sup\u003eLu-PSMSA-617, \u003csup\u003e177\u003c\/sup\u003eLu-PSMA-I\u0026amp;T and \u003csup\u003e225\u003c\/sup\u003eAc-PSMA).\u003c\/span\u003e\u003c\/p\u003e\r\n\u003cp class=\"MsoNormal\"\u003e\u003cspan style=\"mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US;\"\u003eThanks to his experience, the author facilitated the set-up of targeted treatments in various countries: Baltic and Nordic countries, elsewhere in Europe, North America (Canada), and Africa (e.g. Ghana). The author's involvement in promoting therapy tourism to Finland further highlights his breadth of knowledge and practical experience.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003cp class=\"MsoNormal\"\u003e\u003cspan style=\"mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US;\"\u003eThis book offers valuable insights into the evolving landscape of diagnostic methods and radiopharmaceutical treatments for prostate cancer. With the author's extensive experience and contributions to the field, readers can gain a comprehensive understanding of these advancements and their implications in clinical practice.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\u003cdiv\u003e\n\u003cp class=\"MsoNormal\"\u003e\u003cspan style=\"mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US;\"\u003eProf Kairemo graduated with a MSc (Eng) degree from Helsinki University of Technology (Chemical Engineering) in 1980 before undertaking medical training (MD (86), PhD (93)) at the University of Helsinki, Finland. He undertook specialist training in Clinical Chemistry (94), Nuclear Medicine (96), Health Care Administration (02) and Pharmaceutical Medicine (06) at Helsinki University Central Hospital. He had a post-doctoral research fellowship at Memorial Sloan-Kettering Cancer Center in 1989-93 in New York. Besides homeland Finland he is licensed medical specialist in Norway (1998), Sweden (2001) and Estonia (2010).\u003c\/span\u003e\u003c\/p\u003e\r\n\u003cp class=\"MsoNormal\"\u003e\u003cspan style=\"mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US;\"\u003eProf Kairemo has held posts as Professor in Clinical Chemistry at the Norwegian University of Science and Technology (1998-9), Professor in Nuclear Medicine at Uppsala University Hospital in Sweden (2001-5) and as Head of the Nuclear Medicine Division, Department of Oncology at Helsinki University Central Hospital (2004-9). In 2009-2018, he has been the Chief of Nuclear Medicine and Molecular Radiotherapy (Theragnostics) at the Docrates Cancer Center, in Helsinki. Since 2015 he has acted as Visiting Professor in the Nuclear Medicine Department of The University of Texas MD Anderson Cancer Center, in Houston, TX; last visits in 2019, 2022 and 2023.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003cp class=\"MsoNormal\"\u003e\u003cspan style=\"mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US;\"\u003eProf Kairemo has also held posts in industry, as Medical Director of \u003cem\u003eCTT Cancer Targeting Technologies Oy\u003c\/em\u003e (2001-6), Medical Director of \u003cem\u003eImanext Oy\u003c\/em\u003e (2006-8) and Clinical Director at \u003cem\u003eAdvanced Accelerator Applications\u003c\/em\u003e SA in 2009 (now Novartis Co.).\u003c\/span\u003e\u003c\/p\u003e\r\n\u003cp class=\"MsoNormal\"\u003e\u003cspan style=\"mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US;\"\u003eBesides a few patents prof Kairemo has published more than 250 original publications in peer-reviewed journals. He received the Lifetime Achievement Award from the World Association of Radiopharmaceutical and Molecular Therapy in 2012 and was President of the 7\u003csup\u003eth\u003c\/sup\u003e International Conference on Radiopharmaceutical Therapy held in November 2012 in Levi in Finnish Lapland. In 2014, Dr Kairemo hosted ISORBE Symposium and Workshop “Cell Labelling and Cell Therapies” in Helsinki. He also organized the 14\u003csup\u003eth\u003c\/sup\u003e International Symposium on Radiopharmaceutical Therapy (WARMTH) in November 2018 in Helsinki. He was elected in 2022 as the new President of the WARMTH for 2024-2025.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\u003cbr\u003e\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublication Date: \u003c\/td\u003e\n\u003ctd\u003e15 May 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublisher: \u003c\/td\u003e\n\u003ctd\u003eSpringer Nature Switzerland\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImprint: \u003c\/td\u003e\n\u003ctd\u003eSpringer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eISBN-13: \u003c\/td\u003e\n\u003ctd\u003e9783031903397\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFormat: \u003c\/td\u003e\n\u003ctd\u003ePaperback \/ softback\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePage Count: \u003c\/td\u003e\n\u003ctd\u003e233\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e","brand":"Springer Nature Switzerland","offers":[{"title":"Default Title","offer_id":51033404211340,"sku":"9783031903397","price":98.99,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0710\/9545\/1788\/files\/9783031903397.jpg?v=1782489421","url":"https:\/\/fh90cf-fv.myshopify.com\/products\/9783031903397","provider":"Late Knight Books and Services, LLC","version":"1.0","type":"link"}